Rapport Therapeutics Enters Material Definitive Agreement
Ticker: RAPP · Form: 8-K · Filed: Sep 10, 2025 · CIK: 2012593
| Field | Detail |
|---|---|
| Company | Rapport Therapeutics, Inc. (RAPP) |
| Form Type | 8-K |
| Filed Date | Sep 10, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $26.00, $234.7 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement
TL;DR
Rapport Therapeutics signed a big deal, details TBD.
AI Summary
On September 9, 2025, Rapport Therapeutics, Inc. entered into a material definitive agreement. The filing does not disclose specific details of the agreement or any associated dollar amounts or parties involved.
Why It Matters
This filing indicates a significant business development for Rapport Therapeutics, potentially impacting its future operations and strategic direction.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing regarding the material definitive agreement introduces uncertainty about its nature and potential impact.
Key Players & Entities
- Rapport Therapeutics, Inc. (company) — Registrant
- September 9, 2025 (date) — Date of earliest event reported
FAQ
What is the nature of the material definitive agreement entered into by Rapport Therapeutics, Inc.?
The filing does not specify the nature of the material definitive agreement.
Who are the other parties involved in this material definitive agreement?
The filing does not disclose the names of the other parties involved in the agreement.
Are there any financial terms or dollar amounts associated with this agreement?
The filing does not provide any information on financial terms or dollar amounts related to the agreement.
When was this material definitive agreement entered into?
The agreement was entered into on September 9, 2025.
What is the purpose of this 8-K filing?
This 8-K filing is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, reporting the entry into a material definitive agreement and financial statements/exhibits.
Filing Stats: 1,217 words · 5 min read · ~4 pages · Grade level 13.8 · Accepted 2025-09-10 17:22:34
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share RAPP The Nasdaq
- $26.00 — Stock"), at a public offering price of $26.00 per share. In addition, the Company has
- $234.7 m — e by the Company, will be approximately $234.7 million, excluding any proceeds from exer
Filing Documents
- d907117d8k.htm (8-K) — 33KB
- d907117dex11.htm (EX-1.1) — 214KB
- d907117dex51.htm (EX-5.1) — 8KB
- g907117g0910234832207.jpg (GRAPHIC) — 3KB
- 0001193125-25-200205.txt ( ) — 436KB
- rapp-20250909.xsd (EX-101.SCH) — 3KB
- rapp-20250909_lab.xml (EX-101.LAB) — 18KB
- rapp-20250909_pre.xml (EX-101.PRE) — 11KB
- d907117d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "will" and "would" and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements contained in this Current Report on Form 8-K, such as those related to the anticipated closing of the Offering and use of proceeds, are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this Current Report on Form 8-K, including, without limitation, uncertainties related to market conditions and the satisfaction of customary closing conditions related to the Offering. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the Company's Annual Report on Form 10-K and most recent Quarterly Report on Form 10-Q, as well as any subsequent filings with the SEC. Any forward-looking statements represent Rapport's views only as of today and should not be relied upon as representing its views as of any subsequent date. Rapport expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in t
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 1.1 Underwriting Agreement, dated September 9, 2025, by and between Rapport Therapeutics, Inc. and Goldman Sachs & Co. LLC, Jefferies LLC, TD Securities (USA) LLC and Stifel, Nicolaus & Company, Incorporated. 5.1 Opinion of Goodwin Procter LLP 23.1 Consent of Goodwin Procter LLP (included in Exhibit 5.1) 104 Cover Page Interactive Data File (embedded within Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Rapport Therapeutics, Inc. Date: September 10, 2025 By: /s/ Troy Ignelzi Troy Ignelzi Chief Financial Officer